Fig. S3.

miR-211–5p expression is solely dependent on BRAF inhibition and not on cellular cytotoxicity. (A) Dose–response curve for dabrafenib treatment in MML-1 cells. The relative percent of cell viability was assessed with an MTT assay. (B) Cell count analysis of MML-1 cells treated with different units of UV exposure (J/m²). (C) Total RNA profiles of cells after different treatment conditions using Nano Chip and Bioanalyzer. All cellular profiles showed RIN values of 10 with no degradation of rRNA. (D–G) Fold change of miR-211–5p in cells and extracellular vesicles after vemurafenib (200 nM), dabrafenib (100 nM), UV (80 J/m²), and cotreatments normalized to the external spike-in, C. elegans miR-39–3p (n = 3). (H–K) Fold change of miR-211–5p in cells and extracellular vesicles after vemurafenib (200 nM), qVD-OPH (pan-caspase inhibitor), and cotreatments normalized to the external spike-in C. elegans miR-39–3p (n = 3). Ns, nonsignificant; wrt, with respect to. Data are presented as ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.